HeraMED Limited (HeraMED or the Company) announced that Sheba Medical Centre, Israel's largest hospital has initiated a pilot to test both the HeraBEAT device and HeraCARE platform. The pilot will be undertaken at the Sheba Medical Centre at Tel-Hashomer, a university-affiliated tertiary referral hospital that serves as Israel's national medical centre in many fields. The pilot involves several defined stages. During the first stage, which begins immediately, Sheba will use the HeraBEAT smart pregnancy monitors in operational mode to enable telehealth-based services in their dedicated pregnancy COVID-19 unit. Pregnant women who are admitted to the Covid-19 unit require continuous monitoring. The HeraBEAT monitors will enable real-time foetal and maternal heart rate monitoring and analysis by Sheba's midwives and obstetricians, limiting the amount of physical interaction to potentially reduce the risk of COVID-19 exposure and spread. The second stage of the pilot will involve a much wider study providing additional use cases beyond COVID-19 such as high-risk pregnancies and post-term in which constant and real-time remote pregnancy monitoring is necessary. This stage holds significant potential to include a wide audience of pregnant women. This pilot will further include both in-hospital as well as in-home used-cases, and it is a part of Sheba BEYOND's vision to become a leader in virtual care and home admission services. During the first stage of the pilot, each party will cover its own costs; HeraMED will work closely with the professional team at Sheba to ensure the technology is successfully integrated into their workflows and IT infrastructure. This work is expected to underpin an efficient adoption for the anticipated full-scale, commercial deployment.